Ioannis Alexopoulos
Overview
Explore the profile of Ioannis Alexopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
318
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muller J, Kromer A, Ezaddoustdar A, Alexopoulos I, Steinegger K, Porras-Gonzalez D, et al.
ACS Appl Mater Interfaces
. 2025 Feb;
17(8):11861-11872.
PMID: 39938880
Biodegradable poly(β-amino) esters (PBAEs) have been a focus of interest for delivering therapeutic siRNA for several years. While no approved therapies are on the market yet, our study aims to...
2.
Khadim A, Kiliaris G, Vazquez-Armendariz A, Procida-Kowalski T, Glaser D, Bartkuhn M, et al.
Cell Rep
. 2025 Feb;
44(2):115248.
PMID: 39903667
Alveolar regeneration requires the coordinated engagement of epithelial stem cells and mesenchymal niche cells to restore the intricate alveolar architecture of the lung. The current paradigm is that certain aspects...
3.
Ament A, Heiner M, Hessler M, Alexopoulos I, Steeg K, Gartner U, et al.
Am J Respir Cell Mol Biol
. 2024 Sep;
72(2):124-132.
PMID: 39226154
Organoid three-dimensional systems are powerful platforms to study development and disease. Recently, the complexity of lung organoid models derived from adult mouse and human stem cells has increased substantially in...
4.
Vasquez-Pacheco E, Marega M, Lingampally A, Fassy J, Truchi M, Goth K, et al.
Theranostics
. 2024 Jul;
14(9):3603-3622.
PMID: 38948058
Myofibroblasts (MYFs) are generally considered the principal culprits in excessive extracellular matrix deposition and scar formation in the pathogenesis of lung fibrosis. Lipofibroblasts (LIFs), on the other hand, are defined...
5.
Zabihi M, Khadim A, Schafer T, Alexopoulos I, Bartkuhn M, El Agha E, et al.
Cells
. 2024 Jun;
13(11.
PMID: 38891054
Organoid models have become an integral part of the research methodology in the lung field. These systems allow for the study of progenitor and stem cell self-renewal, self-organization, and differentiation....
6.
Henneke I, Pilz C, Wilhelm J, Alexopoulos I, Ezaddoustdar A, Mukhametshina R, et al.
Am J Physiol Cell Physiol
. 2024 Apr;
326(6):C1637-C1647.
PMID: 38646782
Bleomycin (BLM)-induced lung injury in mice is a valuable model for investigating the molecular mechanisms that drive inflammation and fibrosis and for evaluating potential therapeutic approaches to treat the disease....
7.
Chu X, Kheirollahi V, Lingampally A, Chelladurai P, Valasarajan C, Vazquez-Armendariz A, et al.
Circ Res
. 2024 Apr;
134(11):e133-e149.
PMID: 38639105
Background: The precise origin of newly formed ACTA2+ (alpha smooth muscle actin-positive) cells appearing in nonmuscularized vessels in the context of pulmonary hypertension is still debatable although it is believed...
8.
Pervizaj-Oruqaj L, Selvakumar B, Ferrero M, Heiner M, Malainou C, Glaser R, et al.
Nat Commun
. 2024 Jan;
15(1):87.
PMID: 38167746
Influenza A virus (IAV) infection mobilizes bone marrow-derived macrophages (BMDM) that gradually undergo transition to tissue-resident alveolar macrophages (TR-AM) in the inflamed lung. Combining high-dimensional single-cell transcriptomics with complex lung...
9.
Adams F, Zimmermann C, Baldassi D, Pehl T, Weingarten P, Kachel I, et al.
Small
. 2023 Dec;
20(22):e2308775.
PMID: 38126895
RNA interference (RNAi) is an efficient strategy to post-transcriptionally silence gene expression. While all siRNA drugs on the market target the liver, the lung offers a variety of currently undruggable...
10.
Wygrecka M, Hadzic S, Potaczek D, Alexopoulos I, El Agha E, Schaefer L
Pol Arch Intern Med
. 2023 Jun;
133(7-8).
PMID: 37387676
Idiopathic pulmonary fibrosis (IPF) is a progressive and life‑threatening interstitial lung disease of familial or sporadic onset. The incidence and prevalence of IPF range from 0.09 to 1.3 and from...